Tarsus Pharmaceuticals (NASDAQ:TARS) Rating Lowered to Hold at Wall Street Zen

Tarsus Pharmaceuticals (NASDAQ:TARS) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price on the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Barclays assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.00.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $75.52 on Friday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25. The firm has a market cap of $3.21 billion, a PE ratio of -46.62 and a beta of 0.55. The company’s 50 day moving average is $72.00 and its two-hundred day moving average is $68.84.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. On average, research analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares of the company’s stock, valued at $3,120,535.80. This represents a 15.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.97% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Large investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $368,000. Invesco Ltd. boosted its holdings in shares of Tarsus Pharmaceuticals by 8.0% in the fourth quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock valued at $82,892,000 after acquiring an additional 75,351 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $202,000. XTX Topco Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 270.3% in the 4th quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock valued at $1,507,000 after acquiring an additional 13,438 shares during the period. Finally, Squadron Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $6,550,000. 90.01% of the stock is owned by institutional investors and hedge funds.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.